Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to
pain management and JanOne's development of non-addicting
treatments for pain
LAS
VEGAS, Aug. 31, 2023 /PRNewswire/ -- JanOne
(Nasdaq: JAN), the biopharmaceutical company focused on developing
non-addicting painkillers and novel treatments for the causes of
pain, will participate in investor sessions at the H.C. Wainwright
25th Annual Global Investment Conference in
New York City. JanOne's Chief
Medical Officer, Dr. Amol Soin, will
appear via recorded video and attend the conference in person to
represent the company's mission and progress.
Dr. Soin's virtual presentation will be shown September 11 — 13th and will be
accessible on the JanOne.com website in subsequent days.
This week, on August 29, JanOne announced that it had
received a US Patent for its use of its novel formulation of
low-dose naltrexone, Jan123, to treat chronic pain. Tony Isaac, JanOne's CEO, noted that the new
patent's broad language—covering methods of using JanOne's
formulation of low-dose naltrexone to treat chronic pain—"provides
robust and broad coverage and protection, and lengthens the
timeline for sales significantly."
Also last week, on August 25,
Dr. Soin announced that his team had won a prestigious "Best
Abstract" award for reporting that JanOne's treatment for diabetic
neuropathy showed both effectiveness against pain and potential to
improve nerve function. The abstract, which was presented at the
annual meeting of the Ohio Society of Interventional Pain
Physicians (OHSIPP), one of the nation's largest regional pain
management meetings, analyzed prior data on Jan101's randomized
double blind placebo-controlled trial in diabetic neuropathy
patients.
About JanOne Inc.
JanOne is a unique
Nasdaq-listed company offering innovative, actionable solutions
intended to help end the opioid crisis. JanOne is dedicated to
funding resources toward innovation, technology, and education to
find a key resolution to the national opioid epidemic, which is one
of the deadliest and most widespread in the nation's history. Its
drugs in the clinical trial pipeline have shown promise for their
innovative targeting of the causes of pain as a strategic option
for physicians averse to exposing patients to addictive
opioids.
Please visit www.janone.com for additional
information.
Forward Looking Statements
This press release contains statements that are forward-looking
statements as defined within the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
relating to the statements that JAN 101 will treat PAD, that JAN
123 will treat CRPS, the timing of the commencement of clinical
trials, that the FDA will permit approval through a 505(b)(2)
pathway for JAN 123, that upon approval JAN 101 will immediately
disrupt the PAD market, and other statements, including words such
as "continue", "expect", "intend", "will", "hope" "should",
"would", "may", "potential" and other similar expressions. Such
statements reflect JanOne's current view with respect to future
events, are subject to risks and uncertainties, and are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable by JanOne, are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause JanOne's
actual results, performance or achievements to be materially
different from any future results, performance or achievements
described in this press release. Such factors could include, among
others, those detailed in the Company's periodic reports filed with
the Securities and Exchange Commission (the "SEC"). Should one or
more of these risks or uncertainties materialize, or should the
assumptions set out in the section entitled "Risk Factors" in
JanOne's filings with the SEC underlying those forward-looking
statements prove incorrect, actual results may vary materially from
those described herein. These forward-looking statements are made
as of the date of this press release and JanOne does not intend,
and does not assume any obligation, to update these forward-looking
statements, except as required by law. JanOne cannot assure that
such statements will prove to be accurate as actual results and
future events could differ materially from those anticipated in
such statements. Individuals are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty
therein.
Media Contact Investor Relations
IR@janone.com
1-800-400-2247
View original content to download
multimedia:https://www.prnewswire.com/news-releases/janone-to-present-in-person-and-by-video-at-hc-wainwrights-25th-annual-global-investment-conference-301914628.html
SOURCE JanOne Inc.